Abingdon Health (LSE:ABDX) is heading into its Annual General Meeting after a year of faster growth and a narrower loss. On 11 November 2026 the diagnostics contract developer and manufacturer published notice of its AGM and made its 2026 Annual Report available. That followed its final results on 13 October 2026. Those results showed higher revenue, better margins and an expanding US business, although the company also flagged some short-term delays at the start of its new financial year.

What the company does

Abingdon Health (LSE:ABDX) is a contract development and Manufacturing organisation (CDMO) that specialises in diagnostic tests. It works with healthcare and life sciences customers to develop and make their tests, with services running from early product development through to large-scale manufacturing. In recent years it has expanded into the US. It has opened a manufacturing hub in Madison, Wisconsin, and in April 2026 its shares were admitted to trading on the OTCQB market in the US.

Latest developments

Revenue for the year to 30 June 2026 rose 32% to £11.3m. Contract development Revenue increased 56% to £5.0m. Gross Margin improved to 47.1%, and the company said adjusted EBITDA was positive in the second half. The loss before tax narrowed to £2.0m from £3.5m. Cash rose to £2.9m, helped by Equity fundraising of £3.2m.

Looking ahead, management said there had been some short-term delays in the first quarter of the 2027 financial year. It still expects revenue to keep growing and EBITDA to improve over the year as a whole.

The company has made several operational announcements in the past few months. On 25 September it marked the official opening of its US manufacturing hub in Madison. The Facility is intended to meet growing Demand for diagnostic tests made in the US, and local and state officials attended the opening. On 29 September it announced that it had gained UKAS ISO/IEC 17025 accreditation, a recognised standard for testing laboratories. Earlier in 2026, it announced a US tax Credit agreement in May. It also gave an update on its Partnership with 4TEEN4 Pharmaceuticals, and UpFront Diagnostics launched its LVOne stroke test, which Abingdon is involved with.

Financial picture

The company has made progress towards profitability but is not there yet. A positive EBITDA in the second half is an important milestone for a Business of this size. However, it still made a loss for the full year, and its cash position depends in part on money raised from shareholders.

Sector and index context

Abingdon is a small healthcare company within the FTSE AIM All Share Index. The diagnostics CDMO market has settled down since the swings caused by pandemic-era testing. Growth now depends on winning development projects that later turn into manufacturing contracts. Interest in onshoring medical manufacturing in the US is the opportunity its Wisconsin site is meant to capture.

Key risks

Development projects can slip, as the first-quarter delays show, and this makes revenue uneven. The company may need more Capital if growth or margins fall short of plan. Running sites in both the UK and the US also adds cost and complexity to execution.

What to watch next

The upcoming AGM may bring a trading statement. Investors will be looking for evidence that the first-quarter delays have been made up, that the US hub is winning work, and that the company can sustain positive EBITDA through the 2027 financial year.